(59 days)
The TracStar LDP Large Distal Platform is indicated for the introduction of interventional devices into the peripheral. coronary, and neuro vasculature.
The Zoom 88 Large Distal Platform and Zoom 88 Large Distal Platform Support are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
The Imperative Care Large Distal Platform™ (LDP) Catheters include the Zoom™ 88 Large Distal Platform™, Zoom™ 88 Large Distal Platform™ Support, and TracStar™ LDP Large Distal Platform. The LDP Catheters are 0.038" diameter or smaller guidewire compatible single lumen guide catheters that provide access to peripheral, coronary and neuro vasculature. The catheters are comprised of a hollow cylindrical tube bonded at the proximal end to a standard luer fitting. The wall of the tube is constructed using a combination of metal coils/braids and medical grade polymers. The distal section of each catheter has a hydrophilic coating to enhance tracking through tortuous vasculature. An angled distal soft tip facilitates smooth tracking past vessel branches. A radiopaque marker provides visual confirmation of the distal tip location under fluoroscopy. The LDP Catheters have an inner diameter (ID) of 0.088" (6F compatible), and a maximum outer diameter (OD) of 0.110". The LDP guide catheters are packaged with a rotating hemostasis valve (RHV) that is attached to the proximal luer to help maintain hemostasis.
This document describes the acceptance criteria and the study conducted to demonstrate that the TracStar™ LDP Large Distal Platform, Zoom™ 88 Large Distal Platform, and Zoom™ 88 Large Distal Platform Support devices meet these criteria.
1. Table of Acceptance Criteria and Reported Device Performance
The device is a medical catheter, and the performance evaluation involved a series of bench and laboratory (in-vitro) tests to ensure its safety and effectiveness. The acceptance criteria are "Pass" for all tested attributes, meaning the device met the specified performance requirements.
| Test Attribute | Specification | Reported Device Performance |
|---|---|---|
| Delivery, Compatibility, and Retraction (Trackability) | The catheter shall be able to be delivered, deployed, and retracted per the IFU within a simulated neurological model without incurring any damage to the catheter. | Pass |
| Tip Flexibility | The catheter distal tip flexibility shall be comparable to the predicate. | Pass |
| Visual Inspection | The catheter shall meet visual inspection criteria. The printing on the strain relief must be legible. | Pass |
| Dimensional (Distal ID, Proximal ID, Distal OD, Proximal OD) | All defined catheter dimensions are within the specified tolerances. | Pass |
| Catheter Bond Strength | The catheter shall have sufficient bond strengths to remain intact throughout a procedure. | Pass |
| Freedom from Leakage - Positive Pressure | The catheter must remain leak free under specified test conditions. | Pass |
| Freedom from Leakage - Negative Pressure | The catheter must remain leak free under specified test conditions. | Pass |
| Burst Pressure | The catheter must withstand pressure testing under dynamic flow conditions. | Pass |
| Static Burst | The catheter shall meet criteria for static burst pressure testing. | Pass |
| Catheter Torque Strength | With the catheter tip constrained from movement, the proximal end was rotated until failure. The catheter shall not be damaged when rotated at least two (2) full rotations (720 degrees). | Pass |
| Kink Resistance | There shall be no kinking of the catheter shaft around respective clinically relevant minimum bend radii in distal tip, medial and proximal locations. | Pass |
| Flexibility | The catheters need to have acceptable flexure values for tracking in the vasculature. | Pass |
| Proximal Shaft Stiffness | The stiffness of the proximal shaft was evaluated to ensure comparable stiffness to the predicate. | Pass |
| Delivery Force | The catheters shall not be too stiff or require excessive force to safely navigate and track to the target neurovasculature. | Pass |
| Compatibility with other Devices (External) | The catheters shall be able to be delivered through the minimum introducer sheath or guide catheter size indicated in the product labeling. | Pass |
| Guidewire Compatibility | The catheters shall be able to be delivered over the maximum size guidewire indicated in the product labeling. | Pass |
| Interventional Device Compatibility (internal) | The catheters shall be able to accommodate other interventional devices (e.g., support catheter, diagnostic catheter) up to the maximum size indicated in the product labeling. | Pass |
| Luer Compatibility | Devices and accessories shall be compatible with standard syringe luer fittings per ISO 80369-7. | Pass |
| Accessory Compatibility | Devices shall be compatible with an RHV. | Pass |
| Coating - Particulate | The amount of particulate matter generated during simulated use testing shall be determined and compared to competitive products and techniques. | Pass |
| Coating - Lubricity, Durability and Integrity | Coating must be lubricious with a specified average pull force. There were no coating anomalies or significant wear observed post simulated use. | Pass |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify the exact sample sizes for each test attribute. The study relies on bench and laboratory (in-vitro) testing, which typically involves testing a defined number of device units or components to statistical significance or to demonstrate compliance with a specification. The data provenance is prospective as the testing was conducted specifically for this submission to evaluate the subject devices. The country of origin of the data is not explicitly stated but is implied to be where Imperative Care, Inc. conducts its R&D and testing.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
This information is not applicable as the study involves bench and laboratory (in-vitro) testing of physical device properties against established engineering and performance specifications, not human interpretation of medical data. Therefore, there is no "ground truth" established by medical experts in this context.
4. Adjudication Method for the Test Set
Not applicable, as this was not a human-reader study requiring adjudication of expert opinions. The adjudication for bench testing is typically based on whether the test results meet or exceed the predefined pass/fail criteria.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size
No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This type of study is relevant for diagnostic imaging AI systems where human readers interpret medical images. The current submission pertains to the substantial equivalence of a medical catheter based on physical and mechanical performance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
This question is not applicable to the device described. The device is a physical medical catheter, not a software algorithm. The "standalone" performance refers to the physical and mechanical performance of the catheter itself, which was evaluated through bench and laboratory testing without human "in-the-loop" performance in the context of interpretation or decision-making.
7. The Type of Ground Truth Used
The "ground truth" for this device's evaluation is defined by established engineering and performance specifications based on standards such as ISO 10555-1, as well as internal design requirements. These specifications act as the objective criteria against which the device's performance is measured.
8. The Sample Size for the Training Set
This information is not applicable. The device is a physical medical catheter, not a machine learning or AI algorithm that requires a training set.
9. How the Ground Truth for the Training Set Was Established
This information is not applicable as there is no training set for this type of device.
{0}------------------------------------------------
June 6, 2024
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
Imperative Care, Inc. Kristin Ellis Director, Regulatory Affairs 1359 Dell Avenue, Campbell, California 95008
Re: K240948
Trade/Device Name: TracStar LDP Large Distal Platform; Zoom 88 Large Distal Platform; Zoom 88 Large Distal Platform Support Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: OJP, DQY Dated: April 5, 2024 Received: April 8, 2024
Dear Kristin Ellis:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
{1}------------------------------------------------
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Naira Muradyan -S
Naira Muradyan, Ph.D. Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K240948
Device Name TracStar™ LDP Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Support
Indications for Use (Describe)
The TracStar LDP Large Distal Platform is indicated for the introduction of interventional devices into the peripheral. coronary, and neuro vasculature.
The Zoom 88 Large Distal Platform and Zoom 88 Large Distal Platform Support are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
| Type of Use (Select one or both, as applicable) |
|---|
| Prescription Use (Part 21 CFR 801 Subpart D) |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary
A. Submitter Information
Submitter's Name: Address:
Contact Person: Telephone: Email: Date of Preparation:
B. Subject Device
Proprietary Names:
Common/Usual Name: Classification Name: Product Code:
Regulation:
C. Predicate Device
Proprietary Name:
Common/Usual Name: Classification Name: Product Code:
Regulation: Manufacturer: 510(k) #'s:
Imperative Care, Inc. 1359 Dell Avenue Campbell, CA 95008 Kristin Ellis 408-857-0934 kellis@imperativecare.com June 4, 2024
TracStar™ LDP Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Support Guide Catheter Catheter, Percutaneous, Neurovasculature OJP DQY 21 CFR 870.1250
TracStar™ LDP Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Zoom™ 88 Large Distal Platform™ Support Guide Catheter Catheter, Percutaneous, Neurovasculature OJP DQY 21 CFR. 870.1250 Imperative Care, Inc. K231168
D. Device Description:
The Imperative Care Large Distal Platform™ (LDP) Catheters include the Zoom™ 88 Large Distal Platform™, Zoom™ 88 Large Distal Platform™ Support, and TracStar™ LDP Large Distal Platform. The LDP Catheters are 0.038" diameter or smaller guidewire compatible single lumen guide catheters that provide access to peripheral, coronary and neuro vasculature. The catheters are comprised of a hollow cylindrical tube bonded at the proximal end to a standard luer fitting. The wall of the tube is constructed using a combination of metal coils/braids and medical grade polymers. The distal section of each catheter has a hydrophilic coating to enhance tracking through tortuous vasculature. An
{4}------------------------------------------------
angled distal soft tip facilitates smooth tracking past vessel branches. A radiopaque marker provides visual confirmation of the distal tip location under fluoroscopy. The LDP Catheters have an inner diameter (ID) of 0.088" (6F compatible), and a maximum outer diameter (OD) of 0.110". The LDP guide catheters are packaged with a rotating hemostasis valve (RHV) that is attached to the proximal luer to help maintain hemostasis.
Accessory devices required, but not supplied include:
- . Guidewires
- Support/diagnostic catheters .
- Introducer sheaths .
E. Indications for Use:
The TracStar LDP Large Distal Platform is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
The Zoom 88 Large Distal Platform and Zoom 88 Large Distal Platform Support are indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.
F. Principles of Operation:
The LDP Catheters may be used with support catheters to assist in accessing the target vasculature. During use, the male luer of the RHV is attached to the proximal luer of the LDP Catheter to create a continuous lumen through the catheter and to the RHV ports. The female luer is typically connected to a saline drip line while the LDP Catheter is advanced through the vasculature. Use of the LDP Catheter relies on standard percutaneous interventional techniques, including access site preparation, introducing the catheter portion of the device, advancing the catheter under fluoroscopy, withdrawing the catheter, and closing the access site.
G. Predicate Comparison:
The predicate devices are the Imperative Care 0.088" ID Large Distal Platform (LDP) Catheters cleared under K231168. The predicate and subject devices share the same intended use, basic technological characteristics, and the same performance characteristics, demonstrated through bench and laboratory testing as shown in Table 1.
{5}------------------------------------------------
| Device Attribute | Predicate device | Subject device |
|---|---|---|
| FDA ProductClassification | Class II, QJP andDQY, 21 CFR 870.1250 | Same |
| Product Name | TracStar LDP Large Distal Platform Zoom 88 Large Distal Platform Zoom 88 Large Distal Platform Support | Same |
| 510(k) Number | K231168 | K240948 |
| Indications for Use | The TracStar LDP Large DistalPlatform is indicated for theintroduction of interventionaldevices into the peripheral,coronary, and neuro vasculature.The Zoom 88 Large DistalPlatform and Zoom 88 LargeDistal Platform Support areindicated for the introduction ofinterventional devices into theperipheral, coronary, and neurovasculature. | Same |
| Condition Supplied | Sterile and Single Use | Same |
| Sterilization Method | Ethylene Oxide (EtO), SAL 10-6 | Same |
| Single Cycle | Up to Two (2) Cycles | |
| Inner Diameter(Distal) | 0.088" | Same |
| Outer Diameter(Distal) | 0.106" | Same |
| Inner Diameter(Proximal) | 0.088" | Same |
| Outer Diameter(Proximal) | 0.110" | Same |
| Effective Length | TracStar LDP: 80 – 105 cmZoom 88 LDP: 100 – 110 cmZoom 88 LDP Support: 100 cm | TracStar LDP: 80 – 105 cmZoom 88 LDP: 110 cmZoom 88 LDP Support: 100 cm |
| Tip Design | Beveled distal edge, soft, flexible,atraumatic tip | Same |
| Device Attribute | Predicate device | Subject device |
| Distal Catheter Shaft | Reinforced with metals andpolymers | Same |
| Proximal CatheterShaft | Reinforced with metals andpolymers | Same |
| Coating | Hydrophilic coating | Same |
| Materials | Commonly used medical gradeplastics & metals with hydrophiliccoating | Same |
| PackagedAccessories | Rotating Hemostasis Valve (RHV) | Same |
| PackagingConfiguration | The catheters are placed in aprotective polyethylene tube,mounted with accessory RHV ontoa polyethylene packaging card,placed into a pouch, sealed andlabeled. The sealed pouch and IFUare placed in a labeled shelf cartonbox. | Same |
| Shelf life | 12 months | 36 months |
Table 1: Comparison of Subject and Predicate Devices
{6}------------------------------------------------
H. Performance Data Supporting Substantial Equivalence:
Bench and laboratory (in-vitro) testing was completed to evaluate the differences between the subject LDP Catheters and predicate LDP Catheters. Performance specifications and test methods were based primarily on catheter performance standard ISO 10555-1 and a summary of the evaluated performance specifications is presented in Table 2.
The test results were reviewed and found to demonstrate that the differences between the subject LDP Catheters and predicate LDP Catheters do not significantly impact any performance parameters that would negatively affect the safety or effectiveness of the subject LDP Catheters.
| Test Attribute | Specification | Results |
|---|---|---|
| Delivery, Compatibility,and Retraction(Trackability) | The catheter shall be able to be delivered,deployed, and retracted per the IFU within asimulated neurological model withoutincurring any damage to the catheter. | Pass |
| Table 2: Tests and Performance Specifications | |
|---|---|
| ----------------------------------------------- | -- |
{7}------------------------------------------------
| Test Attribute | Specification | Results |
|---|---|---|
| Tip Flexibility | The catheter distal tip flexibility shall becomparable to the predicate. | Pass |
| Visual Inspection | The catheter shall meet visual inspectioncriteria.The printing on the strain relief must belegible. | Pass |
| Dimensional (Distal ID,Proximal ID, Distal OD,Proximal OD) | All defined catheter dimensions are withinthe specified tolerances. | Pass |
| Catheter Bond Strength | The catheter shall have sufficient bondstrengths to remain intact throughout aprocedure. | Pass |
| Freedom from Leakage- Positive Pressure | The catheter must remain leak free underspecified test conditions. | Pass |
| Freedom from Leakage- Negative Pressure | The catheter must remain leak free underspecified test conditions. | Pass |
| Burst Pressure | The catheter must withstand pressure testingunder dynamic flow conditions. | Pass |
| Static Burst | The catheter shall meet criteria for staticburst pressure testing. | Pass |
| Catheter TorqueStrength | With the catheter tip constrained frommovement, the proximal end was rotateduntil failure. The catheter shall not bedamaged when rotated at least two (2) fullrotations (720 degrees). | Pass |
| Kink Resistance | There shall be no kinking of the cathetershaft around respective clinically relevantminimum bend radii in distal tip, medial andproximal locations. | Pass |
| Flexibility | The catheters need to have acceptableflexure values for tracking in thevasculature. | Pass |
| Proximal Shaft Stiffness | The stiffness of the proximal shaft wasevaluated to ensure comparable stiffness tothe predicate. | Pass |
| Delivery Force | The catheters shall not be too stiff or requireexcessive force to safely navigate and trackto the target neurovasculature. | Pass |
| Test Attribute | Specification | Results |
| Compatibility with otherDevices (External) | The catheters shall be able to be deliveredthrough the minimum introducer sheath orguide catheter size indicated in the productlabeling. | Pass |
| GuidewireCompatibility | The catheters shall be able to be deliveredover the maximum size guidewire indicatedin the product labeling. | Pass |
| Interventional DeviceCompatibility (internal) | The catheters shall be able to accommodateother interventional devices (e.g., supportcatheter, diagnostic catheter) up to themaximum size indicated in the productlabeling. | Pass |
| Luer Compatibility | Devices and accessories shall be compatiblewith standard syringe luer fittings per ISO80369-7. | Pass |
| Accessory Compatibility | Devices shall be compatible with an RHV. | Pass |
| Coating - Particulate | The amount of particulate matter generatedduring simulated use testing shall bedetermined and compared to competitiveproducts and techniques. | Pass |
| Coating - Lubricity,Durability and Integrity | Coating must be lubricious with a specifiedaverage pull force. There were no coatinganomalies or significant wear observed postsimulated use. | Pass |
{8}------------------------------------------------
I. Biocompatibility Testing:
There are no changes to patient contacting materials, including raw materials, manufacturing processes, and manufacturing aids compared to the predicate device. Therefore, the original testing on the predicate devices applies to the subject devices and additional biocompatibility testing was not required.
J. Sterilization:
The LDP Catheters are sterilized using a validated EtO process with a sterility assurance level of 1x10 6 validated per the overkill method in accordance with ISO 11135, "Sterilization Of Health-Care Products - Ethylene Oxide - Requirements For The Development, Validation And Routine Control Of A Sterilization Process For Medical Devices".
{9}------------------------------------------------
K. Shelf Life and Packaging:
Accelerated aging testing based on ASTM F1980 was previously conducted to verify packaged device performance of the predicate LDP Catheters. The subject LDP Catheters undergo the same packaging and similar sterilization processing as the predicate LDP Catheters. The construction of the subject LDP Catheters is the same as the predicate LDP Catheters including raw materials, manufacturing processes, and manufacturing aids. Verification testing of the subject LDP Catheters followed the same test methods as the predicate LDP Catheters. Bench testing of the subject LDP Catheters and packaging supports a three (3) year shelf life.
L. Conclusions:
Where differences were identified between the subject and predicate devices, a risk assessment was completed to determine if the difference would result in new safety or effectiveness concerns. As appropriate, previous bench and laboratory testing was evaluated for applicability and either the rationale for no impact was documented or verification and validation was repeated as required.
Based on the results of the risk assessments and associated bench and laboratory testing. the subject and predicate devices are substantially equivalent and there are no new safety or effectiveness concerns. The subject devices and predicate devices share the same intended use, basic technological characteristics, and performance characteristics.
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).